Optimal pharmacological management of HCM by clinical manifestations
Pablo Garcia-Pavia, MD, PhD
Evidence-based novel therapies in HCM
Michelle Michels, MD
Staging therapy in hypertrophic cardiomyopathy patients with heart failure: New insights
Aleš Linhart, MD, PhD
Recognizing and diagnosing heart failure in patients with HCM
Patient-clinician communication about obesity management
Martha Gulati, MD
Obesity: A looming cardiovascular threat – Pathophysiology, diagnosis and impact
Naveed Sattar, MD, PhD
Discussion
John Deanfield, MD
The weight of cardiovascular risk: Addressing obesity in cardiac patients
Why cardiologists should be interested in obesity and its treatment
ATTR-CM Management: Pearls From Recent Clinical Trials and Tailoring Therapy
Marianna Fontana, MD
Ronald Witteles, MD
ACC 2024: What's Really New in Electrophysiology That Will Change My Practice?
Manesh R. Patel, MD
Key Advances in Heart Health: Insights From the American College of Cardiology 2024 Scientific Sessions
Marc P. Bonaca, MD, MPH
Daniel Gaudet, MD, PhD
Christie M. Ballantyne, MD, FACP, FACC
ACC 2024: VOYAGER PAD Part 2
ACC 2024: VOYAGER PAD Part 1
ACC 2024: SHASTA-2 Final Study Results
Plozasiran (ARO-APOC3) Decreases APOC3 and Triglycerides (TG) in Patients With Mixed Hyperlipidemia: MUIR Final Results
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.